Back to Search
Start Over
ROS-Responsive Nanoparticles Formed from RGD-Epothilone B Conjugate for Targeted Cancer Therapy.
- Source :
-
ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2020 Apr 22; Vol. 12 (16), pp. 18301-18308. Date of Electronic Publication: 2020 Apr 13. - Publication Year :
- 2020
-
Abstract
- The targeted nanoagents have shown great potential clinically for cancer therapy. Traditional targeted nanodrugs are usually prepared through surface postmodification. Herein, a nanodrug is self-assembled from the amphiphilic precursor of targeting peptide RGD conjugated with cytotoxin epothilone B (Epo B) through a linker containing the thioketal (tk) group that is sensitive to reactive oxygen species (ROS). The obtained RGD-tk-Epo B conjugate nanoparticles (RECNs) are stable and uniform, which facilitates improving tumor-targeting capacity and accumulation of the drug because of the large number of RGD on the surface of the RECN. After internalization by cancer cells, the blood-inert tk group between RGD and Epo B can be cleaved in the presence of high level of ROS to release Epo B, exhibiting a markedly tumor selectivity and excellent anticancer efficiency in vitro and in vivo .
- Subjects :
- Animals
Apoptosis drug effects
Cell Line, Tumor
Cell Survival drug effects
Humans
Mice
Neoplasms, Experimental pathology
Xenograft Model Antitumor Assays
Antineoplastic Agents chemistry
Antineoplastic Agents pharmacokinetics
Antineoplastic Agents pharmacology
Epothilones chemistry
Epothilones pharmacokinetics
Epothilones pharmacology
Nanoconjugates chemistry
Oligopeptides chemistry
Reactive Oxygen Species metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1944-8252
- Volume :
- 12
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- ACS applied materials & interfaces
- Publication Type :
- Academic Journal
- Accession number :
- 32242653
- Full Text :
- https://doi.org/10.1021/acsami.0c00650